My Take on The Market This was a good week in the market, which was a welcome relief. We had a big bailout announced by the federal government and some estimates of how bad COVID19 could be came down a...
Q3 2018 Record Billings of $6.3 Million, Up 210% Year over Year and Up 21% from Q2 Q3 2018 Record GAAP Revenue of $4.4 Million, Up 266% Year over Year and up 33% from Q2 Reiterates 2018 Billings...
Los Angeles, California—May 24, 2017—Catasys, Inc. (NASDAQ: CATS), a provider of proprietary predictive analytics and integrated treatment solutions to health insurance plans, announced today that it has launched enrollment under the previously announced contract for its OnTrak™-C solution coverage...
October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from several disastrous meltdowns. These include Black Monday in 1987 when the market lost 23% in...
In the twenty-first century, AI techniques have experienced a massive surge in interest following concurrent advances in computer power, large amounts of data, and theoretical understanding. Companies are focused on it, Google has rebuilt their software around it, and Mark Zuckerberg...
Tailwinds' Take: launching into treatment of another disorder demonstrates the potential of the OnTrak platform for horizontal expansion across any behavioral health issue. Catasys is in the early stages of a massive opportunity. Los Angeles, CA – May 9, 2019...
Tailwinds' Take: Catasys is executing on their plan. Adding states to existing programs demonstrates that they are having success. Management's comments give increasing confidence to rapid growth in Q3 and beyond. Catasys, Inc. (CATS), a provider of proprietary predictive analytics...
Tailwinds' Take: as evidenced by many recent articles, including today's WSJ, the opioid epidemic is one of the largest problems facing our country. Catasys' OnTrak program is a potential life saver for those suffering from addiction.  Catasys, Inc. (CATS), a provider...

Visions of 2020

This last week was actually a very good week for the Tailwinds' portfolio. Despite the overall quiet of a holiday week (or maybe because of it?), led by a 22% gain in Provention Bio, we managed to put up...
On June 27, 2017, Catasys' CEO Terren Peizer spoke with Tailwinds partner Daniel Carlson, discussing the current business of CATS, the growth plans, and the competitive landscape. Tailwinds has a $16.20 target on CATS and it's a member of...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.